Randomized trials show immune checkpoint blockade with transarterial chemoembolization improves outcomes in liver-limited hepatocellular carcinoma, suggesting new treatment directions.
Key Points
Combining immune checkpoint inhibition with transarterial chemoembolization results in improved outcomes.
Randomized studies showed superior progression free survival compared to chemoembolization alone.
Phase 1/2 trials confirm the safety of this combined approach for intermediate stage liver cancer.
Further research is necessary to identify ideal candidate profiles for these treatments.